S M Rybak1, H R Hoogenboom, H M Meade
1Biochemistry Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20896.
Researchers created a novel antibody-enzyme fusion protein targeting the transferrin receptor. This engineered immunotoxin effectively kills cancer cells expressing the transferrin receptor, showing promise for new cancer therapies.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: